Overview

A Study of IMC008 for Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2026-03-31

Target enrollment:

Participant gender:

Summary

An open label, multi-center, dose-escalating study to evaluate the safety and preliminary efficacy of IMC008 in CLDN18.2 positive advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Changhai Hospital